ICMS Announces RMI Accreditation


This e-mail address is being protected from spambots. You need JavaScript enabled to view it

International Cell Medicine Society Accredits Regenerative Medicine Institute

PORTLAND, OREGON – Friday, February 24, 2012. The International Cellular Medicine Society (ICMS), a professional medical association dedicated to patient safety through the strict evaluation of cell-based therapies and the rigorous oversight of medical facilities and clinics has granted the status of “Accredited” to the Regenerative Medicine Institute (RMI) of Tijuana, Mexico.

“We are pleased that RMI undertook this process,” says David Audley, executive director of the ICMS. “The clinic understood that patient safety can only be assured through strict evaluation and rigorous oversight. From day one they have embraced the transparency that this program requires.”

RMI is the first clinic to achieve this status under the ICMS Accreditation Program. The clinic has undergone two separate site audits and undergone an institutional review board review evaluation. Most importantly, the clinic has placed in excess of 50 patients into the Treatment Registry for long-term outcome tracking.  “The safety profile has been excellent,” continued Audley. “We have tracked patients over at least two follow ups and a minimum of six months and not seen a single cell-related adverse event.”

The ICMS is currently evaluating nearly a dozen clinics worldwide. Accreditation is based upon the Guidelines for the Practice of Cell-Based Medicine developed and published by the ICMS. Key components of these guidelines are the ethical recruitment of patients, the proper consenting of patients and compliance with local laws and regulations in the treatment of patients.



The ICMS is a 501(c)(3) nonprofit professional medical organization that is focused on the development of standards for the evaluation of point-of-care, cell-based therapeutics worldwide. With over 3,500 members from over 35 countries, the ICMS is a global leader in patient safety through strict evaluation of therapies and rigorous oversight of clinics and facilities providing cell-based medical therapies. The ICMS maintains an independent Institutional review Board and manages a comprehensive Treatment Registry that tracks patient outcomes. More information can be found at www.cellmedicinesociety.org,

DISCLAIMER:  Cell-based medical therapies are an investigational treatment. All medical treatments carry risk. Patients are urged to consult with their physicians to weigh the risks prior to undergoing any investigational treatment. Accreditation by the ICMS should not be taken as a recommendation to seek treatment or substitute advice provided by a licensed and qualified physician.